FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138977263> ?p ?o ?g. }

• W3138977263 endingPage "4485" @default.
• W3138977263 startingPage "4478" @default.
• W3138977263 abstract "Abstract On December 20, 2019, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki [DS-8201a; T-DXd; tradename ENHERTU (Daiichi Sankyo)] for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting. Approval was based on data from study DS8201-A-U201 (DESTINY-Breast01) with supportive safety data from study DS8201-A-J101. The primary efficacy endpoint in DESTINY-Breast01 was overall response rate (ORR) based on confirmed responses by blinded independent central review (ICR) using RECIST v1.1 in all participants who were assigned to receive the recommended dose of 5.4 mg/kg while secondary endpoints included duration of response (DoR). The confirmed ORR based on ICR in these 184 patients was 60.3% [95% confidence interval (CI): 52.9–67.4] and the median DoR was 14.8 months (95% CI: 13.8–16.9). Interstitial lung disease, including pneumonitis, was experienced in patients treated with T-DXd and can be severe, life threatening, or fatal. In addition, neutropenia and left ventricular dysfunction were included as Warnings and Precautions in labeling. Other important common adverse reactions were nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, diarrhea, and thrombocytopenia. Overall, the totality of efficacy and safety data supported the accelerated approval of T-DXd for the intended indication." @default.
• W3138977263 created "2021-03-29" @default.
• W3138977263 creator A5004000071 @default.
• W3138977263 creator A5020171435 @default.
• W3138977263 creator A5021532388 @default.
• W3138977263 creator A5028716935 @default.
• W3138977263 creator A5030426478 @default.
• W3138977263 creator A5031131979 @default.
• W3138977263 creator A5035436218 @default.
• W3138977263 creator A5042471290 @default.
• W3138977263 creator A5043067852 @default.
• W3138977263 creator A5050956552 @default.
• W3138977263 creator A5051520990 @default.
• W3138977263 creator A5062916090 @default.
• W3138977263 creator A5067347250 @default.
• W3138977263 creator A5069297078 @default.
• W3138977263 creator A5073413471 @default.
• W3138977263 creator A5074097054 @default.
• W3138977263 creator A5077762257 @default.
• W3138977263 creator A5086876495 @default.
• W3138977263 creator A5089126800 @default.
• W3138977263 date "2021-03-22" @default.
• W3138977263 modified "2023-10-16" @default.
• W3138977263 title "FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer" @default.
• W3138977263 cites W2110444464 @default.
• W3138977263 cites W2137228442 @default.
• W3138977263 cites W2155333216 @default.
• W3138977263 cites W2159427817 @default.
• W3138977263 cites W2159967578 @default.
• W3138977263 cites W2314772071 @default.
• W3138977263 cites W2810369514 @default.
• W3138977263 cites W2889646458 @default.
• W3138977263 cites W2996630100 @default.
• W3138977263 cites W3005585857 @default.
• W3138977263 cites W3018222852 @default.
• W3138977263 doi "https://doi.org/10.1158/1078-0432.ccr-20-4557" @default.
• W3138977263 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8570919" @default.
• W3138977263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33753456" @default.
• W3138977263 hasPublicationYear "2021" @default.
• W3138977263 type Work @default.
• W3138977263 sameAs 3138977263 @default.
• W3138977263 citedByCount "53" @default.
• W3138977263 countsByYear W31389772632021 @default.
• W3138977263 countsByYear W31389772632022 @default.
• W3138977263 countsByYear W31389772632023 @default.
• W3138977263 crossrefType "journal-article" @default.
• W3138977263 hasAuthorship W3138977263A5004000071 @default.
• W3138977263 hasAuthorship W3138977263A5020171435 @default.
• W3138977263 hasAuthorship W3138977263A5021532388 @default.
• W3138977263 hasAuthorship W3138977263A5028716935 @default.
• W3138977263 hasAuthorship W3138977263A5030426478 @default.
• W3138977263 hasAuthorship W3138977263A5031131979 @default.
• W3138977263 hasAuthorship W3138977263A5035436218 @default.
• W3138977263 hasAuthorship W3138977263A5042471290 @default.
• W3138977263 hasAuthorship W3138977263A5043067852 @default.
• W3138977263 hasAuthorship W3138977263A5050956552 @default.
• W3138977263 hasAuthorship W3138977263A5051520990 @default.
• W3138977263 hasAuthorship W3138977263A5062916090 @default.
• W3138977263 hasAuthorship W3138977263A5067347250 @default.
• W3138977263 hasAuthorship W3138977263A5069297078 @default.
• W3138977263 hasAuthorship W3138977263A5073413471 @default.
• W3138977263 hasAuthorship W3138977263A5074097054 @default.
• W3138977263 hasAuthorship W3138977263A5077762257 @default.
• W3138977263 hasAuthorship W3138977263A5086876495 @default.
• W3138977263 hasAuthorship W3138977263A5089126800 @default.
• W3138977263 hasBestOaLocation W31389772631 @default.
• W3138977263 hasConcept C121608353 @default.
• W3138977263 hasConcept C126322002 @default.
• W3138977263 hasConcept C141071460 @default.
• W3138977263 hasConcept C143998085 @default.
• W3138977263 hasConcept C197934379 @default.
• W3138977263 hasConcept C203092338 @default.
• W3138977263 hasConcept C2775930923 @default.
• W3138977263 hasConcept C2776694085 @default.
• W3138977263 hasConcept C2777063308 @default.
• W3138977263 hasConcept C2777714996 @default.
• W3138977263 hasConcept C2779524853 @default.
• W3138977263 hasConcept C2779786085 @default.
• W3138977263 hasConcept C2780580376 @default.
• W3138977263 hasConcept C2781112942 @default.
• W3138977263 hasConcept C530470458 @default.
• W3138977263 hasConcept C535046627 @default.
• W3138977263 hasConcept C71924100 @default.
• W3138977263 hasConcept C90924648 @default.
• W3138977263 hasConceptScore W3138977263C121608353 @default.
• W3138977263 hasConceptScore W3138977263C126322002 @default.
• W3138977263 hasConceptScore W3138977263C141071460 @default.
• W3138977263 hasConceptScore W3138977263C143998085 @default.
• W3138977263 hasConceptScore W3138977263C197934379 @default.
• W3138977263 hasConceptScore W3138977263C203092338 @default.
• W3138977263 hasConceptScore W3138977263C2775930923 @default.
• W3138977263 hasConceptScore W3138977263C2776694085 @default.
• W3138977263 hasConceptScore W3138977263C2777063308 @default.
• W3138977263 hasConceptScore W3138977263C2777714996 @default.
• W3138977263 hasConceptScore W3138977263C2779524853 @default.
• W3138977263 hasConceptScore W3138977263C2779786085 @default.
• W3138977263 hasConceptScore W3138977263C2780580376 @default.
• W3138977263 hasConceptScore W3138977263C2781112942 @default.

• next